Below is a list of SINAPPS Group studies both current and closed
STUDY OF IMMUNOLOGY IN ANTIBODY POSITIVE PSYCHOSIS 2 (SINAPPS2)
The SINAPP2 trial is a randomised, placebo-controlled clinical trial, investigating the efficacy and safety of immunotherapy as a treatment for symptoms of psychosis in patients with anti-neuronal membrane antibodies.
Prevalence of Pathogenic Antibodies in Psychosis 2 (PPiP2)
The aim of the PPiP2 study is to assess large number of people suffering from psychosis and identify those with anti-neuronal membrane antibodies in their serum which might be causing their illness. Participants with anti-neuronal membrane antibodies will be invited to take part in the SINAPPS2 trial.
STUDY OF IMMUNOLOGY IN ANTIBODY POSITIVE PSYCHOSIS 1 (SINAPPS1)
SINAPPS1 was a phase-one open label study and it investigated the feasibility of delivering immunotherapy to patients with psychosis in a general hospital setting. The study was conducted from October 2015 to July 2017.
PREVALENCE OF PATHOGENIC ANTIBODIES IN PSYCHOSIS 1 (PPIP1)
The PPiP1 study investigated prevalence of patients with anti-neuronal membrane antibodies included who were experiencing their first episode of psychosis in comparison with a group of healthy participants. The study was conducted from January 2013 to December 2014.